Response: Screening for treatable disease is better than just screening for hemochromatosis.

Response: Screening for treatable disease is better than just screening for hemochromatosis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Response: Screening for treatable disease is better than just screening for hemochromatosis. Abstract Text:

Jill Waalen,Vincent J Felitti,Terri Gelbart,Ernest Beutler,Jill Waalen,Vincent J Felitti,Terri Gelbart,Ernest Beutler,

Response: Screening for treatable disease is better than just screening for hemochromatosis. Publishing Authors By Initials

J Waalen,VJ Felitti,T Gelbart,E Beutler,J Waalen,VJ Felitti,T Gelbart,E Beutler,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Response: Screening for treatable disease is better than just screening for hemochromatosis. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Blood

VOLUME: 111

Page Numbers: 3897

Journal Abbreviation: Blood

ISSN: 0006-4971

DAY: 1

MONTH: Apr

YEAR: 2008

Response: Screening for treatable disease is better than just screening for hemochromatosis. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7603509

Response: Screening for treatable disease is better than just screening for hemochromatosis. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Response: Screening for treatable disease is better than just screening for hemochromatosis. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Response: Screening for treatable disease is better than just screening for hemochromatosis.

AFFILIATION:

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Blood

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Response: Screening for treatable disease is better than just screening for hemochromatosis Related Publications

• A new case of human atransferrinemia with a previously undescribed mutation in the transferrin gene.
• A proinflammatory mediator with potential relevance in aging.
• ATP-sensitive potassium channels mediate survival during infection in mammals and insects.
• Autosomal inactivation.
• Chromosomal constitution in glucose-6-phosphatate-dehydrogenase deficiency.
• Cladribine.
• Different regulatory elements are required for response of hepcidin to interleukin-6 and bone morphogenetic proteins 4 and 9.
• Effects of alcohol consumption on iron metabolism in mice with hemochromatosis mutations.
• Forward genetic analysis of TLR-signaling pathways: An evaluation.
• Gaucher disease: multiple lessons from a single gene disorder.
• Genetic analysis of innate immunity.
• Glucose-6-phosphate dehydrogenase deficiency: a historical perspective.
• Hepcidin mimetics from microorganisms? A possible explanation for the effect of Helicobacter pylori on iron homeostasis.
• Human chitotriosidase polymorphisms G354R and A442V associated with reduced enzyme activity.
• In vivo imaging of hepcidin promoter stimulation by iron and inflammation.
• Intrathecal long-term gene expression by self-complementary adeno-associated virus type 1 suitable for chronic pain studies in rats.
• Iron storage disease: facts, fiction and progress.
• Iron-overload-related disease in HFE hereditary hemochromatosis.
• Jinx, an MCMV susceptibility phenotype caused by disruption of Unc13d: a mouse model of type 3 familial hemophagocytic lymphohistiocytosis.
• KLF6 degradation after apoptotic DNA damage.
• Neo-ligands for innate immune receptors and the etiology of sterile inflammatory disease.
• Response of the fever of Hodgkin's disease to nitrogen mustard (NSC-762): an evaluation of its significance.
• Response: Screening for treatable disease is better than just screening for hemochromatosis.
• Screening for hemochromatosis by measuring ferritin levels: a more effective approach.
• Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain.
• Soluble transferrin receptor-1 levels in mice do not affect iron absorption.
• The distal location of the iron responsive region of the hepcidin promoter.
• The role of STAT, AP-1, E-box and TIEG motifs in the regulation of hepcidin by IL-6 and BMP-9: lessons from human HAMP and murine Hamp1 and Hamp2 gene promoters.
• The serine protease TMPRSS6 is required to sense iron deficiency.
• Toll-like receptors and their place in immunology. Where does the immune response to infection begin?